ALPIX Stock Overview
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pixium Vision SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.38 |
| 52 Week High | €9.55 |
| 52 Week Low | €0.071 |
| Beta | 0.95 |
| 1 Month Change | 0% |
| 3 Month Change | 401.87% |
| 1 Year Change | -86.34% |
| 3 Year Change | -99.59% |
| 5 Year Change | -99.54% |
| Change since IPO | -99.91% |
Recent News & Updates
Shareholder Returns
| ALPIX | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.7% |
| 1Y | -86.3% | 9.0% | 3.2% |
Return vs Industry: ALPIX underperformed the French Medical Equipment industry which returned 22.6% over the past year.
Return vs Market: ALPIX underperformed the French Market which returned 5.5% over the past year.
Price Volatility
| ALPIX volatility | |
|---|---|
| ALPIX Average Weekly Movement | 74.3% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALPIX's share price has been volatile over the past 3 months.
Volatility Over Time: ALPIX's weekly volatility has increased from 69% to 74% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 40 | Lloyd Diamond | www.pixium-vision.com |
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh.
Pixium Vision SA Fundamentals Summary
| ALPIX fundamental statistics | |
|---|---|
| Market cap | €1.53m |
| Earnings (TTM) | -€10.52m |
| Revenue (TTM) | €1.80m |
0.9x
P/S Ratio-0.1x
P/E RatioIs ALPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPIX income statement (TTM) | |
|---|---|
| Revenue | €1.80m |
| Cost of Revenue | €0 |
| Gross Profit | €1.80m |
| Other Expenses | €12.32m |
| Earnings | -€10.52m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.58 |
| Gross Margin | 100.00% |
| Net Profit Margin | -584.66% |
| Debt/Equity Ratio | -127.5% |
How did ALPIX perform over the long term?
See historical performance and comparison